NASDAQ:PTIProteostasis Therapeutics Stock Price, Forecast & News

Proteostasis Therapeutics' stock was trading at $1.16 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PTI shares have increased by 12.1% and is now trading at $1.30. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteostasis Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Proteostasis Therapeutics.

Proteostasis Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Proteostasis Therapeutics.

Proteostasis Therapeutics Inc (NASDAQ:PTI) released its earnings results on Friday, May, 15th. The company reported ($0.19) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.26) by $0.07. View Proteostasis Therapeutics' earnings history.

5 brokers have issued 1-year price targets for Proteostasis Therapeutics' shares. Their forecasts range from $4.00 to $8.00. On average, they anticipate Proteostasis Therapeutics' share price to reach $5.75 in the next twelve months. This suggests a possible upside of 342.3% from the stock's current price. View analysts' price targets for Proteostasis Therapeutics.

Press coverage about PTI stock has been trending very negative this week, according to InfoTrie. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Proteostasis Therapeutics earned a news sentiment score of -3.4 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutProteostasis Therapeutics.

Proteostasis Therapeutics saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 2,630,000 shares, a drop of 6.1% from the April 30th total of 2,800,000 shares. Based on an average trading volume of 1,060,000 shares, the days-to-cover ratio is presently 2.5 days. Currently, 6.2% of the company's stock are short sold. View Proteostasis Therapeutics' Current Options Chain.

Some companies that are related to Proteostasis Therapeutics include OrganiGram (OGI), Avadel Pharmaceuticals (AVDL), Concert Pharmaceuticals (CNCE), Evofem Biosciences (EVFM), Urovant Sciences (UROV), Verastem (VSTM), Bicycle Therapeutics (BCYC), Neptune Wellness Solutions (NEPT), AMAG Pharmaceuticals (AMAG), Agile Therapeutics (AGRX), CymaBay Therapeutics (CBAY), Galera Therapeutics (GRTX), Abeona Therapeutics (ABEO), Osmotica Pharmaceuticals (OSMT) and Chiasma (CHMA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include BHP Group (BHP), Idera Pharmaceuticals (IDRA), Amarin (AMRN), Micron Technology (MU), Rite Aid (RAD), Clearside Biomedical (CLSD), Sorrento Therapeutics (SRNE), vTv Therapeutics (VTVT), Anavex Life Sciences (AVXL) and Syndax Pharmaceuticals (SNDX).

(PTI) raised $51 million in an initial public offering (IPO) on Thursday, February 11th 2016. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."

Proteostasis Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include WINTON GROUP Ltd (1.30%), Acadian Asset Management LLC (0.70%), Geode Capital Management LLC (0.63%), Two Sigma Advisers LP (0.32%), RBF Capital LLC (0.32%) and GSA Capital Partners LLP (0.32%). Company insiders that own Proteostasis Therapeutics stock include Enterprise Associates 12 New, Franklin M Berger, Meenu Chhabra and Po Shun Lee. View institutional ownership trends for Proteostasis Therapeutics.

PTI stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, and WINTON GROUP Ltd. View insider buying and selling activity for Proteostasis Therapeutics.

PTI stock was purchased by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Two Sigma Investments LP, Acadian Asset Management LLC, RBF Capital LLC, Two Sigma Advisers LP, and Connor Clark & Lunn Investment Management Ltd.. View insider buying and selling activity for Proteostasis Therapeutics.

Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PTI stock can currently be purchased for approximately $1.30.

Proteostasis Therapeutics has a market capitalization of $67.79 million and generates $5 million in revenue each year. The company earns $-59,130,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Proteostasis Therapeutics employs 44 workers across the globe.

The official website for Proteostasis Therapeutics is www.proteostasis.com.

Proteostasis Therapeutics' mailing address is 80 Guest Street Suite 500, Boston MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected]